ALKEM2024-07-012024-09-30 ALKEM2024-07-012024-09-30 ALKEM2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member ALKEM2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member ALKEM2024-09-30 ALKEM2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2024-04-01 2025-03-31 2024-11-13 2024-11-05 INR Millions Half yearly 11:00:00 13:00:00 2024-11-13 2024-11-13 true Cash Flow Indirect Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2024-07-01 2024-09-30 Unaudited Consolidated 34146700000.00 1344800000.00 35491500000.00 9021700000.00 3539200000.00 -513900000.00 6104900000.00 281400000.00 789100000.00 8466500000.00 27688900000.00 7802600000.00 0.00 7802600000.00 1558800000.00 -775800000.00 783000000.00 0.00 7019600000.00 0.00 0.00 0.00 0.00 7019600000.00 61000000.00 7080600000.00 6886400000.00 133200000.00 6954900000.00 125700000.00 239100000.00 2 57.60 57.60 0.00 0.00 57.60 57.60 1. The above unaudited consolidated financial results are prepared in accordance wilh the lndian Accounting Standards prescribed under section 133 of the Companies Act, 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial results are prepared in accordance with Ind AS 110 'Consolidated Financial Statements'. 2. The above unaudited consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 12 November 2024 and subsequently approved by the Board of Directors at its meeting held on 13 November 2024. The auditors have issued an unmodified review report on the financial results for the quarter and six months ended 30 September 2024. 3. The comparative financial information of the Group for the quarter ended 30 June 2024, comparative quarter and six months ended 30 September 2023 and for the year ended 31 March 2024, prepared in accordance with Ind AS included in this statement have been reviewed/ audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09 August 2024, 07 November 2023 and 29 May 2024 respectively. 4. Exceptional item for the quarter ended 30 September 2023 included impairment loss of Rs 576.6 Million towards its plant located at St. Louis, USA. Exceptional items for the year ended 31 March 2024 included impairment loss of Rs 576.6 Million and Rs 415.6 Million towards its plant located at St. Louis, USA and Indore respectively and net loss of Rs 222.7 Million (net of recovery) on account of cyber security. In the current quarter ended 30 September 2024, the Parent Company as part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale. 5. As approved by the Members of the Parent Company at the Annual General Meeting held on 30 August 2024, the Company has disbursed a final dividend of Rs 5 (Rupees Five Only) per equity share (face value of Rs 2 each). 6. The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment information has been made. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 64464900000.00 2547900000.00 67012800000.00 17393300000.00 7365800000.00 -1952600000.00 12127600000.00 572500000.00 1593900000.00 15916100000.00 53016600000.00 13996200000.00 0.00 13996200000.00 2803100000.00 -1328900000.00 1474200000.00 0.00 12522000000.00 0.00 0.00 0.00 0.00 12522000000.00 102100000.00 12624100000.00 12338000000.00 184000000.00 12450600000.00 173500000.00 239100000.00 2 103.20 103.20 0.00 0.00 103.20 103.20 Other Expenses 8466500000.00 Other Expenses 15916100000.00 4172300000.00 20128500000.00 2918900000.00 0.00 4192000000.00 3022800000.00 723000000.00 0.00 0.00 8234300000.00 0.00 0.00 2748900000.00 10983200000.00 16532600000.00 1576500000.00 60077500000.00 29121800000.00 3366300000.00 24981100000.00 4125800000.00 15396700000.00 146900000.00 24507600000.00 72524400000.00 0.00 8100300000.00 109746500000.00 1346300000.00 0.00 171170300000.00 239100000.00 114689400000.00 114928500000.00 119100800000.00 1259500000.00 0.00 5621500000.00 6881000000.00 3173600000.00 0.00 0.00 238900000.00 10293500000.00 11103200000.00 18862500000.00 7098100000.00 37063800000.00 2293500000.00 1493100000.00 862700000.00 41713100000.00 62900000.00 52069500000.00 171170300000.00 572500000.00 -2510000000.00 -2513800000.00 0.00 0.00 306000000.00 0.00 0.00 0.00 2028800000.00 0.00 0.00 0.00 1593900000.00 0.00 160100000.00 0.00 0.00 0.00 -141000000.00 1600000.00 1810200000.00 0.00 -193200000.00 0.00 0.00 221700000.00 0.00 0.00 -2286800000.00 11709400000.00 0.00 0.00 0.00 2291500000.00 0.00 9417900000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 85400000.00 3065400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15627900000.00 23315300000.00 0.00 0.00 0.00 0.00 1600000.00 1683900000.00 0.00 3600000.00 0.00 -8978300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 916600000.00 2895000000.00 188600000.00 0.00 622300000.00 420700000.00 0.00 0.00 -3210000000.00 -2770400000.00 159900000.00 -2610500000.00 663100000.00 -1947400000.00 Remeasurements of defined benefit plans -66400000.00 Remeasurements of defined benefit plans -116200000.00 -66400000.00 -116200000.00 -21400000.00 -37400000.00 Foreign currency translation difference of foreign operations 106000000.00 Foreign currency translation difference of foreign operations 180900000.00 106000000.00 180900000.00 0.00 0.00